The case began when India first rejected Novartis's patent application in 2006 for Glivec, known in the U.S. as Gleevec. The legal fight has been a closely watched struggle highlighting the ...

Novartis appealed, arguing Glivec was a newer, more easily absorbed version of the drug and qualified for a fresh patent. Anand Grover, a lawyer for the Cancer Patients Aid Association, which has ...

Key Takeaways Alternating Glivec and Stivarga did not improve survival outcomes and increased toxicity in advanced GIST patients. Both treatment arms showed similar response rates, but the alternating ...

Glivec is currently approved for the treatment of all phases of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (:CML). It is also approved for the treatment of KIT+GIST, which ...

Glivec® is also approved in the EU, US, Japan and more than 70 other countries for the treatment of patients with Kit (CD 117)-positive unresectable (inoperable) and/or metastatic malignant GISTs.

Charles Sawyers, one of the researchers who helped develop the breakthrough cancer drug Glivec, has a new potential hit: the prostate cancer drug MDV3100 from Medivation. Like several other ...

Glivec, which is called Gleevec in the U.S., was first approved in the U.S. and Europe in 2001 as a second-line therapy for CML patients for whom standard chemotherapy has failed.

NICE has reversed a long-standing block on using Glivec in GIST tumours, saying new evidence has persuaded it to change its mind. Final draft guidance published today proposes to recommend ...

Generic versions of Glivec in India cost about one-tenth what Novartis charges for the drug every month, which is approximately 105,000 rupees ($2,600). That price is fixed globally, give or take ...

Glivec study gives hope of cure for some leukemia By Reuters October 20, 20106:50 AM PDTUpdated October 20, 2010 ...

NEW DELHI (Reuters) – Swiss drugmaker Novartis told India’s top court it had demonstrated the improved efficacy of its cancer drug Glivec as the final hearing began on Tuesday of a patent case ...